Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

DYRK2 anticorps (N-Term)

DYRK2 Reactivité: Humain WB, IHC (p) Hôte: Lapin Polyclonal RB3008 unconjugated
N° du produit ABIN391770
  • Antigène Voir toutes DYRK2 Anticorps
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Épitope
    • 15
    • 11
    • 8
    • 7
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 105-135, N-Term
    Reactivité
    • 42
    • 32
    • 22
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 55
    • 7
    • 1
    Lapin
    Clonalité
    • 56
    • 7
    Polyclonal
    Conjugué
    • 26
    • 5
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp DYRK2 est non-conjugé
    Application
    • 56
    • 33
    • 27
    • 13
    • 13
    • 8
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogène
    This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2.
    Clone
    RB3008
    Isotype
    Ig Fraction
  • Indications d'application
    WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
    Date de péremption
    6 months
  • Mimoto, Imawari, Hirooka, Takeyama, Yoshida: "Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer." dans: Oncogene, Vol. 36, Issue 13, pp. 1862-1872, (2017) (PubMed).

    Nomura, Suzuki, Takahashi, Terasaki, Kimata, Terasaki, Hamasaki, Kimura, Shimizu, Kondo: "Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy." dans: BMC urology, Vol. 15, pp. 53, (2015) (PubMed).

    Moreno, Lara-Chica, Soler-Torronteras, Caro, Medina, Álvarez, Salvatierra, Muñoz, Calzado: "The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer." dans: PLoS ONE, Vol. 10, Issue 11, pp. e0143376, (2015) (PubMed).

    Enomoto, Yamashita, Yoshinaga, Fukami, Miyahara, Nabeshima, Iwasaki: "Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer." dans: Tumour biology, Vol. 35, Issue 11, pp. 11021-5, (2014) (PubMed).

    Taira, Mimoto, Kurata, Yamaguchi, Kitagawa, Miki, Yoshida: "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells." dans: The Journal of clinical investigation, Vol. 122, Issue 3, pp. 859-72, (2012) (PubMed).

    Pérez, García-Limones, Zapico, Marina, Schmitz, Muñoz, Calzado: "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways." dans: Journal of molecular cell biology, Vol. 4, Issue 5, pp. 316-30, (2012) (PubMed).

    Yamashita, Chujo, Tokuishi, Anami, Miyawaki, Yamamoto, Kawahara: "Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma." dans: The Journal of thoracic and cardiovascular surgery, Vol. 138, Issue 6, pp. 1303-8, (2009) (PubMed).

    Yamashita, Chujo, Moroga, Anami, Tokuishi, Miyawaki, Kawano, Takeno, Yamamoto, Kawahara: "DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer." dans: Anticancer research, Vol. 29, Issue 7, pp. 2753-7, (2009) (PubMed).

  • Antigène
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Autre désignation
    DYRK2 (DYRK2 Produits)
    Synonymes
    anticorps DYRK2, anticorps fc18c09, anticorps si:ch211-266a5.8, anticorps wu:fa09g03, anticorps wu:fc18c09, anticorps 1810038L18Rik, anticorps dual specificity tyrosine phosphorylation regulated kinase 2, anticorps dual specificity tyrosine-phosphorylation-regulated kinase 2, anticorps dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2, anticorps DYRK2, anticorps CpipJ_CPIJ014802, anticorps dyrk2, anticorps Dyrk2
    Sujet
    DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro.
    Poids moléculaire
    66652
    ID gène
    8445
    NCBI Accession
    NP_003574, NP_006473
    UniProt
    Q92630
    Pathways
    Regulation of Carbohydrate Metabolic Process
Vous êtes ici:
Support technique